1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow ENV-101: new trials by email Literature Review of ENV-101 trials Research Report on ENV-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants taladegib, nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Recruiting | Endeavor Biomedicines, Inc. | 57 | 2026-04-28 | 2026-05-15 |
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Active not recruiting | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-02-24 |
| A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects taladegib, nintedanib - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Endeavor Biomedicines, Inc. | 21 | 2023-05-03 | 2023-12-15 |
Idiopathic Pulmonary Fibrosis (3) · Pulmonary Fibrosis (2)
Endeavor Biomedicines, Inc. (3)
Australia (3) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Malaysia (1) · Mexico (1) · New Zealand (1) · South Korea (1) · United Kingdom (1)
Lisa Lancaster, M.D. (2) · Paul Frohna, M.D., Ph.D. (1)